^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RAS mutation

    2d
    Impact of Co-Mutations and Genetic Variations on Malignancy Risk in RAS-Positive Indeterminate Thyroid Nodules: an Institutional Experience. (PubMed, Endocr Pathol)
    Co-occurring genetic alterations with RAS mutations markedly increased the risk of malignancy compared with isolated RAS mutations (Fisher's exact test, two-tailed p = 0.0026) and were associated with more aggressive tumor phenotypes, whereas isolated RAS mutations were more common in indolent neoplasms. Comprehensive molecular profiling is essential for accurate risk stratification and management of indeterminate thyroid nodules.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • RAS (Rat Sarcoma Virus) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    KRAS mutation • NRAS mutation • RAS mutation • HRAS mutation
    2d
    A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1/2, N=58, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Dec 2025 --> Dec 2027
    Trial initiation date
    |
    RAS mutation
    |
    cytarabine
    2d
    A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=542, Recruiting, Sanofi | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF mutation • HER-2 negative • RAS mutation
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • Yervoy (ipilimumab) • SAR445877 • muzastotug (ADG126)
    3d
    Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Chinese PLA General Hospital
    New P2 trial
    |
    RAS mutation
    |
    Erbitux (cetuximab) • Kolupin (tunlametinib) • TheraCIM (nimotuzumab)
    3d
    FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Oncolytics Biotech
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Reolysin (pelareorep)
    3d
    ARETHUSA: Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (clinicaltrials.gov)
    P2, N=107, Completed, IFOM ETS - The AIRC Institute of Molecular Oncology | Active, not recruiting --> Completed
    Trial completion • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MSI-H/dMMR • RAS mutation • MGMT promoter methylation
    |
    Keytruda (pembrolizumab) • temozolomide
    7d
    Study of BPI-572070 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1/2 trial
    |
    RAS mutation
    7d
    SEACRAFT-1: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Erasca, Inc. | Trial completion date: Nov 2025 --> Dec 2026
    Trial completion date
    |
    RAS mutation
    |
    Mekinist (trametinib) • naporafenib (ERAS-254)
    7d
    Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer. (PubMed, Oncologist)
    The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.
    P1 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • RAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine
    8d
    Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma. (PubMed, bioRxiv)
    As such, the BCL-2 inhibitor venetoclax further enhanced RMC-6236-mediated killing by disrupting RMC-6236 enhanced BIM:BCL-2 complexes. RMC-6236 is a clinically relevant drug that can successfully target the MAPK pathway in these cancers. This study supports expanded clinical testing of this novel therapy to this important subset of neuroblastoma.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • NF1 (Neurofibromin 1) • BCL2L11 (BCL2 Like 11)
    |
    RAS mutation • ALK mutation
    |
    Venclexta (venetoclax) • daraxonrasib (RMC-6236)
    8d
    Association of Cancer-Associated Venous Thromboembolism with the Primary Site of Colorectal Cancer, with Respect to KRAS/NRAS/BRAF Mutations. (PubMed, Biomedicines)
    Right-sided tumor location is an independent predictor of VTE in patients with mCRC and confers a high absolute thrombotic risk not captured by the Khorana score. Incorporating tumor sidedness into VTE risk assessment may improve identification of patients who could benefit from primary thromboprophylaxis.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation
    8d
    Prognostic Scores for Liver Resection in Colorectal Metastases: Performance, Limitations, and Methodological Pitfalls-A Systematic Review and Meta-Analysis. (PubMed, Cancers (Basel))
    The current survival prediction relies on scores with low reliability (C-index ≤ 0.65). Despite the abundance of available data, their heterogeneity and variable quality have limited their usability. Future research should prioritize the development of new prognostic tools and the standardization of prognostic modeling and reporting.
    Retrospective data • Review • Journal
    |
    RAS (Rat Sarcoma Virus)
    |
    RAS mutation